1382748-98-2

Upstream product

• 1382748-90-4 2,4-dioxo-3,4-dihydro-1,3-benzoxazine-6-yl acetate 
• 1382748-92-6 4-(3-chloro-4-fluorophenylamino)-2-oxo-1,3-benzoxazine-6-yl acetate 
• 1382748-96-0 4-(3-chloro-4-fluorophenylimino)-3-methyl-2-oxo-3,4-dihydro-1,3-benzoxazine-6-yl acetate 
• 2150-46-1 Methyl 2,5-dihydroxybenzoate 
• 490-79-9 2,5-dihydroxybenzoic acid. 

Downstream Products

• 1382748-88-0 4-(3-chloro-4-fluorophenylimino)-3-methyl-6-(3-morpholinopropoxy)-3,4-dihydro-1,3-benzoxazine-2-one 

Relevant academic research and scientific papers

Design and Synthesis of Novel EGFR Inhibitors with L-Rhamnose–Benzoxazinone Hybrids

Four L-rhamnose–benzoxazinone compounds as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors were designed and synthesized. All structures of the compounds were characterized by1H-NMR,13C-NMR, and high-resolution mas

Synthesis of novel benzoxazinone compounds as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

(Chemical Equation Presented) Two benzoxazinone compounds as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors were synthesized and characterized by NMR and high-resolution mass spectrometry (HRMS). An efficient chlorination method was introduced in the synthesis of 4-chloro-2-oxo-2H- benzoxazinone-6-yl acetate. The inhibition activities of the target compounds and the important intermediates for EGFR tyrosine kinase activity in vitro were determined. Copyright Taylor & Francis Group, LLC.